J&J Proposes Public-Private Initiative To Advance OTC Monograph Work
This article was originally published in The Rose Sheet
An FDA guidance provides a viable framework for a public-private partnership to facilitate progress in the OTC monograph system, according to J&J consumer business executives. At the same FDA hearing on improving OTC drug review, CHPA leadership stressed that “moving away from the monograph system when we are so close to the end” would “risk setting back the OTC drug review many years or even decades.”
You may also be interested in...
Only 6% of children emptied medicine bottles with flow restrictors in 10 minutes, compared to 82% who emptied bottles with incompletely closed child-resistant caps within two minutes, a CDC study shows. But researchers and stakeholders suggest waiting for industry standards to implement flow restrictors.
“When COVID-19 hit, we really decided to accelerate plans,” says BlueWillow CEO Dave Peralta. NanoBio Protect contains OTC monograph ingredient benzalkonium chloride in a proprietary nanotechnology, alcohol-free formulation to help reduce germs on skin inside and around the nose that could cause infections.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.